Clinical Trial

A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA). Participants are assigned to 1 of 2 cohorts. In cohort 1, participants will receive baricitinib or tocilizumab reference. In cohort 2, participants will receive baricitinib.
Protocol Amendment History 3 changes
critical Trial status changed: RECRUITING → ACTIVE_NOT_RECRUITING 2026-07-17
notable Primary completion pushed: 2026-09 -> 2026-10 2026-07-17
minor Completion pushed: 2026-09 -> 2026-10 2026-07-17
Trial Details
NCT Number NCT04088396
Lead Sponsor Eli Lilly and Company
Conditions Systemic Juvenile Idiopathic Arthritis
Enrollment 58 participants
Start Date 2020-02-12
Primary Completion 2026-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-16